Serum biomarkers in nonalcoholic steatohepatitis: Value for assessing drug effects?

Biomarkers in Medicine

Volumn 6, Issue 6, 2012, Pages 743-757

  Heeringa, Marten ^a   Hastings, Ann ^b   Yamazaki, Shunji ^c   De Koning, Paul ^a  

^a Astellas Pharma Global Development   (Netherlands)

^b Applied Pharmacology Research Laboratories   (Netherlands)

^c ASTELLAS PHARMA INC   (Japan)

Author keywords

apoptosis; biomarkers; cirrhosis; drug development; fatty liver; fibrosis; insulin resistance; NAFLD; NASH; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; oxidative stress; steatosis; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CASPASE 3; CASPASE 7; CASPASE INHIBITOR; COLLAGEN TYPE 4; GLUCOSE; HYALURONIC ACID; INTERLEUKIN 6; METFORMIN; NIVOCASAN; PENTOXIFYLLINE; PIOGLITAZONE; PLACEBO; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; ROSIGLITAZONE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; VX 166;

APOPTOSIS; BIOASSAY; CELL DEATH; CLINICAL EFFECTIVENESS; CLINICAL RESEARCH; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; HEPATITIS; HEPATITIS C; HISTOPATHOLOGY; HUMAN; INSULIN RESISTANCE; INVASIVE PROCEDURE; KINESIOTHERAPY; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; LIVER NECROSIS; LIVER PROTECTION; METABOLIC SYNDROME X; NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; RISK FACTOR; TOXIC HEPATITIS; TREATMENT OUTCOME; UPREGULATION;

ANIMALS; APOPTOSIS; BIOLOGICAL MARKERS; FATTY LIVER; FIBROSIS; HUMANS; TREATMENT OUTCOME;

EID: 84870946062     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.12.87     Document Type: Review

References (88)

1. Browning JD, Szczepaniak LS, Dobbins R et al. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology 40, 1387-1395 (2004
2. Vernon G, Baranova A, Younossi ZM. Systematic review: The epidemiology and natural history of non-Alcoholic fatty liver disease and non-Alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther. 34(3), 274-285 (2011
3. Yilmaz Y. NAFLD in the absence of metabolic syndrome: Different epidemiology, pathogenetic mechanisms, risk factors for disease progressioñSemin. Liver Dis. 32, 14-21 (2012
4. Sanyal AJ, Brunt EM, Kleiner DE et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 54(1), 344-353 (2011
5. Younossi Z, Lavine JE, Diehl AM et al. The diagnosis and management of non-Alcoholic fatty liver disease: Practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142(7), 1592-1609 (2012
6. Koek GH, Liedorp PR, Bast A. The role of oxidative stress in non-Alcoholic steatohepatitis. Clin. Chim. Acta 412(15-16), 1297-1305 (2011
7. Dowman JK, Tomlinson JW, Newsome PN. Systematic review: The diagnosis and staging of non-Alcoholic fatty liver disease and nonalcoholic steatohepatitis. Aliment. Pharmacol. Ther. 33(5), 525-540 (2011
8. Belfort R, Harrison SA, Brown K et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 355(22), 2297-2307 (2006
9. Sanyal AJ, Chalasani N, Kowdley KV et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 362, 1675-1685 (2010
10. Ratziu V, de Ledinghen V, Oberti F et al. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J. Hepatol. 54(5), 1011-1019 (2011
11. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 94(9), 2467-2474 (1999
12. Kleiner DE, Brunt EM, Van Natta M et al.; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41(6), 1313-1321 (2005
13. Nomura K, Yano E, Shinozaki T, Tagawa K. Efficacy and effectiveness of liver screening program to detect fatty liver in the periodic health check-ups. J. Occup. Health 46(6), 423-428 (2004
14. Yano E, Tagawa K, Yamaoka K, Mori M. Test validity of periodic liver function tests in a population of Japanese male bank employees. J. Clin. Epidemiol. 54(9), 945-951 (2001
15. Fracanzani AL, Valenti L, Bugianesi E et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes. Hepatology 48 (3), 792-798 (2008
16. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30(6), 1356-1362 (1999
17. Yuan X, Waterworth D, Perry Jr. Populationbased genome-Wide association studies reveal six loci influencing plasma levels of liver enzymes. Am. J. Hum. Genet. 83(4), 520-528 (2008
18. Hebbard L, George J. Animal models of nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 8, 34-44 (2011
19. Pathil A, Mueller J, Warth A, Chamulitrat W, Stremmel W. Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease. Hepatology 55, 1369-1378 (2012
20. Kawaguchi K, Sakaida I, Tsuchiya M, Omori K, Takami T, Okita K. Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-Altered lesions in rat liver cirrhosis induced by a choline-deficient l-Amino acid-defined diet. Biochem. Biophys. Res. Commun. 315(1), 187-195 (2004
21. Neuschwander-Tetri BA, Unalp A, Creer MH; Nonalcoholic Steatohepatitis Clinical Research Network. Influence of local reference populations on upper limits of normal for serum alanine aminotransferase levels. Arch. Intern. Med. 168(6), 663-666 (2008
22. Giboney PT. Mildly elevated liver transaminase levels in the asymptomatic patient. Am. Fam. Physician 71(6), 1105-1110 (2005
23. Suzuki A, Lymp J, Sauver JS, Angulo P, Lindor K. Values and limitations of serum aminotransferases in clinical trials of nonalcoholic steatohepatitis. Liver Int. 26(10), 1209-1216 (2006
24. Satapathy SK, Garg S, Chauhan R et al. Beneficial effects of tumor necrosis factoralpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 99(10), 1946-1952 (2004
25. Yalniz M, Bahcecioglu IH, Ataseven H et al. Serum adipokine and ghrelin levels in nonalcoholic steatohepatitis. Mediators Inflamm. 2006(6), 34295 (2006
26. Zhao J, Zhou G, Li M et al. A novel nonalcoholic steatohepatitis animal model featured with insulin resistance, hepatic inflammation and fibrosis. Scand. J. Gastroenterol. 45(11), 1360-1371 (2010
27. Kudo H, Takahara T, Yata Y et al. Lipopolysaccharide triggered TNF-Alphainduced hepatocyte apoptosis in a murine non-Alcoholic steatohepatitis model. J. Hepatol. 51(1), 168-175 (2009
28. Kawaratani H, Tsujimoto T, Kitazawa T et al. Innate immune reactivity of the liver in rats fed a choline-deficient l-Amino-Acid-defined diet. World J. Gastroenterol. 14(43), 6655-6661 (2008
29. Lesmana CR, Hasan I, Budihusodo U et al. Diagnostic value of a group of biochemical markers of liver fibrosis in patients with nonalcoholic steatohepatitis. J. Dig. Dis. 10(3), 201-206 (2009
30. Manco M, Marcellini M, Giannone G et al. Correlation of serum TNF-Alpha levels and histologic liver injury scores in pediatric nonalcoholic fatty liver disease. Am. J. Clin. Pathol. 127(6), 954-960 (2007
31. Musso G, Gambino R, Durazzo M et al. Adipokines in NASH: Postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology 42(5), 1175-1183 (2005
32. Hui JM, Hodge A, Farrell GC et al. Beyond insulin resistance in NASH: TNF-Alpha or adiponectiñHepatology 40(1), 46-54 (2004
33. Tokushige K, Takakura M, Tsuchiya-Matsushita N et al. Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis. J. Hepatol. 46(6), 1104-1110 (2007
34. Valenti L, Fracanzani AL, Dongiovanni P et al. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 122(2), 274-280 (2002
35. Yoneda M, Mawatari H, Fujita K et al. High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J. Gastroenterol. 42(7), 573-582 (2007
36. Hui JM, Farrell GC, Kench JG, George J. High sensitivity C-reactive protein values do not reliably predict the severity of histological changes in NAFLD. Hepatology 39(5), 1458-1459 (2004
37. Zimmermann E, Anty R, Tordjman J et al. C-reactive protein levels in relation to various features of non-Alcoholic fatty liver disease among obese patients. J. Hepatol. 55(3), 660-665 (2011
38. Cressman DE, Greenbaum LE, DeAngelis RA et al. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 274(5291), 1379-1383 (1996
39. Mas E, Danjoux M, Garcia V, Carpentier S, Ségui B, Levade T. IL-6 deficiency attenuates murine diet-Induced non-Alcoholic steatohepatitis. Plos One 4, e7929 (2009
40. Jin X, Zimmers TA, Perez EA, Pierce RH, Zhang Z, Koniaris LG. Paradoxical effects of short- And long-Term interleukin-6 exposure on liver injury and repair. Hepatology 43(3), 474-484 (2006
41. Coulon S, Francque S, Colle I et al. Evaluation of inflammatory and angiogenic factors in patients with non-Alcoholic fatty liver disease. Cytokine 59(2), 442-449 (2012
42. Das SK, Balakrishnan V. Role of cytokines in the pathogenesis of non-Alcoholic fatty liver disease. Indian J. Clin. Biochem. 26(2), 202-209 (2011
43. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: A pilot study of the effects of lifestyle modification and vitamin E. Hepatology 38(2), 413-419 (2003
44. Yalniz M, Bahçecioǧlu IH, Kuzu N et al. Amelioration of steatohepatitis with pentoxifylline in a novel nonalcoholic steatohepatitis model induced by high-fat diet. Dig. Dis. Sci. 52(9), 2380-2386 (2007
45. Lindor KD, Kowdley KV, Heathcote EJ et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial. Hepatology 39(3), 770-778 (2004
46. Tuncer Ý, Uygan Ý, Dülger H et al. The comparative effects of pentoxifylline and ursodeoxycholic acid on IL-1, IL-6, IL-8, and TNF-A levels in nonalcoholic fatty liver. Eastern J. Med. 8(2), 27-32 (2003
47. Bantel H, Ruck P, Gregor M, Schulze-Osthoff K. Detection of elevated caspase activation and early apoptosis in liver diseases. Eur. J. Cell Biol. 80(3), 230-239 (2001
48. Feldstein AE, Gores GJ. Apoptosis in alcoholic and nonalcoholic steatohepatitis. Front. Biosci. 10 (3), 3093-3099 (2005
49. Musso G, Gambino R, Pacini G, Pagano G, Durazzo M, Cassader M. Transcription factor 7-like 2 polymorphism modulates glucose and lipid homeostasis, adipokine profile, and hepatocyte apoptosis in NASH. Hepatology 49 (2), 426-435 (2009
50. Feldstein AE, Canbay A, Angulo P et al. Hepatocyte apoptosis and Fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 125(2), 437-443 (2003
51. Inoue Y, Asanuma T, Smith N et al. Modulation of Fas-FasL related apoptosis by PBN in the early phases of choline deficient diet-mediated hepatocarcinogenesis in rats. Free Radic. Res. 9, 972-980 (2007
52. Leers MP, Kölgen W, Björklund V et al. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J. Pathol. 187, 567-572 (1999
53. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 44(1), 27-33 (2006
54. Younossi ZM, Jarrar M, Nugent C et al. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes. Surg. 18(11), 1430-1437 (2008
55. Feldstein AE, Gores GJ. Steatohepatitis and apoptosis: Therapeutic implications. Am. J. Gastroenterol. 99(9), 1718-1719 (2004
56. Joka D, Wahl K, Moeller S et al. Prospective biopsy controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology 55(2), 455-464 (2012
57. Tamimi TI, Elgouhari HM, Alkhouri N et al. An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J. Hepatol. 54, 1224-1229 (2011
58. Witek RP, Stone WC, Karaca FG et al. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. Hepatology 50(5), 1421-1430 (2009
59. Anstee QM, Concas D, Kudo H et al. Impact of pan-caspase inhibition in animal models of established steatosis and non-Alcoholic steatohepatitis. J. Hepatol. 53(3), 542-550 (2010
60. Ratziu V, Sheikh MY, Sanyal AJ et al. A Phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology 55(2), 419-428 (2012
61. Reeves HL, Friedman SL. Activation of hepatic stellate cells - A key issue in liver fibrosis. Front. Biosci. 7, d808-d826 (2002
62. El-Assal O, Hong F, Kim WH, Radaeva S, Gao B. IL-6-deficient mice are susceptible to ethanol-Induced hepatic steatosis: IL-6 protects against ethanol-Induced oxidative stress and mitochondrial permeability transition in the liver. Cell. Mol. Immunol. 1(3), 205-211 (2004
63. Gabele E, Brenner DA, Rippe RA. Liver fibrosis: Signals leading to the amplification of the fibrogenic hepatic stellate cell. Front. Biosci. 8, d69-d77 (2003
64. Teoh N, Field J, Farrell G. Interleukin-6 is a key mediator of the hepatoprotective and pro-proliferative effects of ischaemic preconditioning in mice. J. Hepatol. 45(1), 20-27 (2006
65. Laurent TC, Fraser Jr. Hyaluronan. FASEB J. 6(7), 2397-2404 (1992
66. Eriksson S, Fraser JR, Laurent TC, Pertoft H, Smedsrod B. Endothelial cells are a site of uptake and degradation of hyaluronic acid in the liver. Exp. Cell Res. 144(1), 223-228 (1983
67. Bentsen KD, Henriksen JH, Laurent TC. Circulating hyaluronate: Concentration in different vascular beds in man. Clin. Sci. 71(2), 161-165 (1986
68. Levesque H, Delpech B, Le Loet X, Deshayes P. Serum hyaluronate in rheumatoid arthritis: Study by affino-Immunoenzymatic assay. Br. J. Rheumatol. 27(6), 445-449 (1988
69. Engstrom-Laurent A, Feltelius N, Hallgren R, Wasteson A. Raised serum hyaluronate levels in scleroderma: An effect of growth factor induced activation of connective tissue cells? Ann. Rheum. Dis. 44(9), 614-620 (1985
70. Hallgren R, Eklund A, Engstrom-Laurent A, Schmekel B. Hyaluronate in bronchoalveolar lavage fluid: A new marker in sarcoidosis reflecting pulmonary disease. Br. Med. J. (Clin. Res. Ed.) 290(6484), 1778-1781 (1985
71. Ueno T, Inuzuka S, Torimura T et al. Serum hyaluronate reflects hepatic sinusoidal capillarization. Gastroenterology 105(2), 475-481 (1993
72. Suzuki A, Angulo P, Lymp J, Li D, Satomura S, Lindor K. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-Alcoholic fatty liver disease. Liver Int. 25(4), 779-786 (2005
73. Lydatakis H, Hager IP, Kostadelou E, Mpousmpoulas S, Pappas S, Diamantis I. Non-Invasive markers to predict the liver fibrosis in non-Alcoholic fatty liver disease. Liver Int. 26(7), 864-871 (2006
74. Yoneda M, Mawatari H, Fujita K et al. Type IV collagen 7S domain is an independent clinical marker of the severity of fibrosis in patients with nonalcoholic steatohepatitis before the cirrhotic stage. J. Gastroenterol. 42(5), 375-381 (2007
75. Rosenberg WM, Voelker M, Thiel R et al. Serum markers detect the presence of liver fibrosis: A cohort study. Gastroenterology 127, 1704-1713 (2004
76. Guha IN, Parkes J, Roderick P et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 47(2), 455-460 (2008
77. Parkes J, Roderick P, Harris S et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 59, 1245-1251 (2010
78. Nobili V, Parkes J, Bottazzo G. Performance of ELF serum markers in predicting fibrosis stage in pediatric non-Alcoholic fatty liver disease. Gastroenterology 136(1), 160-167 (2009
79. Baranova A, Lal P, Birerdinc A, Younossi ZM. Non-Invasive markers for hepatic fibrosis. BMC Gastroenterol. 11, 91 (2011
80. Baranova A, Younossi ZM. The future is around the corner: Noninvasive diagnosis of progressive nonalcoholic steatohepatitis. Hepatology 47(2), 373-375 (2008
81. Marchesini G, Bugianesi E, Forlani G et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37(4), 917-923 (2003
82. Ota T, Takamura T, Kurita S et al. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. Gastroenterology 132(1), 282-293 (2007
83. Fracanzani AL, Valenti L, Bugianesi E et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes. Hepatology 48(3), 792-798 (2008
84. Haffner SM, Miettinen H, Stern MP. The homeostasis model in the San Antonio Heart Study. Diabetes Care 20(7), 1087-1092 (1997
85. Day CP, James OF. Steatohepatitis: A tale of two 'hits'? Gastroenterology 114(4), 842-845 (1998
86. Rector RS, Thyfault JP, Wei Y, Ibdah JA. Non-Alcoholic fatty liver disease and the metabolic syndrome: An update. World J. Gastroenterol. 14(2), 185-192 (2008
87. Munteanu M, Ratziu V, Morra R, Messous D, Imbert-Bismut F, Poynard T. Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. J. Gastrointestin. Liver Dis. 17(2), 187-191 (2008
88. Anty R, Bekri S, Luciani N et al. The inflammatory C-reactive protein is increased in both liver and adipose tissue in severely obese patients independently from metabolic syndrome, Type 2 diabetes, and NASH. Am. J. Gastroenterol. 101(8), 1824-1833 (2006